Table S2. Distribution of proteasome activities in women with disease stage II.

Activity	Designation	Gender, women; D. stage, II					Test of normality (p); Interval number 10		
		Valid N	Mean	Min	Max	St. D.	K-S test	Lill. test	S-W test
ChTL	(1)	14	27.86	18.50	35.80	4.98	>0.20	>0.20	0.469
	(2)	14	19.76	14.10	27.90	4.00	>0.20	>0.20	0.129
	(3)	14	6.15	4.00	8.40	1.25	>0.20	>0.20	0.908
	(4)	14	7.19	4.00	11.40	1.86	>0.20	>0.20	0.717
	(5)	14	4.99	2.00	7.40	1.33	>0.20	>0.20	0.870
	(6)	12	8.26	4.20	14.90	3.02	>0.20	<0.05	0.112
	(7)	11	6.74	4.50	10.50	1.68	>0.20	<0.20	0.405
CL	(1)	14	6.16	5.20	7.90	0.83	>0.20	<0.15	0.213
	(2)	14	2.99	2.10	3.80	0.60	>0.20	>0.20	0.230
	(3)	14	1.85	1.50	2.30	0.27	>0.20	<0.10	0.173
	(4)	14	1.83	1.20	2.40	0.39	>0.20	<0.20	0.274
	(5)	14	2.24	1.60	2.70	0.35	>0.20	>0.20	0.460
	(6)	12	1.89	1.30	2.50	0.32	>0.20	>0.20	0.989
	(7)	11	2.17	1.60	3.20	0.53	>0.20	<0.20	0.096
LMP7	(1)	7	13.11	10.10	16.90	2.73	>0.20	<0.20	0.166
	(2)	7	7.59	4.90	11.00	2.65	>0.20	<0.20	0.102
	(3)	7	3.74	0.50	5.80	1.95	>0.20	>0.20	0.588
	(4)	7	2.80	1.00	5.80	1.81	>0.20	>0.20	0.253
	(5)	7	4.27	1.30	7.10	2.02	>0.20	>0.20	0.781
	(6)	6	2.72	1.60	4.20	0.92	>0.20	>0.20	0.769
	(7)	5	3.26	1.60	5.40	1.40	>0.20	>0.20	0.812
LMP2	(1)	7	3.26	1.70	4.80	1.18	>0.20	>0.20	0.585
	(2)	7	1.97	1.00	2.80	0.61	>0.20	>0.20	0.920
	(3)	7	0.33	0.10	0.90	0.29	>0.20	<0.20	0.055
	(4)	7	0.73	0.20	1.30	0.48	>0.20	<0.05	0.042
	(5)	7	0.89	0.20	1.40	0.42	>0.20	>0.20	0.800
	(6)	6	1.20	0.30	2.20	0.77	>0.20	>0.20	0.436
	(7)	5	0.70	0.30	1.50	0.47	>0.20	<0.15	0.168

St. D., Standard deviation; K-S test, Kolmogorov-Smirnov test; Lill. test, Lilliefors test; S-W test, Shapiro-Wilk test.